FILE 'HOME' ENTERED AT 17:03:06 ON 15 AUG 2008

=> file medline biosis polymer embase
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'BIOSIS' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'APOLLIT' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'BABS' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'CAPLUS' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'CBNB' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'CIN' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'COMPENDEX' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'DISSABS' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'EMA' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'IFIPAT' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'NTIS' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'PASCAL' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'PROMT' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'RAPRA' ENTERED AT 17:03:41 ON 15 AUG 2008
COPYRIGHT (C) 2008 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 17:03:41 ON 15 AUG 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'TEXTILETECH' ENTERED AT 17:03:41 ON 15 AUG 2008
COPYRIGHT (C) 2008 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 17:03:41 ON 15 AUG 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:03:41 ON 15 AUG 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:03:41 ON 15 AUG 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 17:03:41 ON 15 AUG 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'WPINDEX' ENTERED AT 17:03:41 ON 15 AUG 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'WSCA' ENTERED AT 17:03:41 ON 15 AUG 2008
COPYRIGHT (C) 2008 PAINT RESEARCH

FILE 'WTEXTILES' ENTERED AT 17:03:41 ON 15 AUG 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 17:03:41 ON 15 AUG 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> s topoisomerse(a)II(a)poison
L1   0 TOPOISOMERSE(A) II(A) POISON

=> s topoisomerase(a)II(a)poison
L2   1540 TOPOISOMERASE(A) II(A) POISON

=> s l2 and (dioxypiperazine or piperazinedione)
L3   21 L2 AND (DIOXYPIPERAZINE OR PIPERAZINEDIONE)

=> dis l3 1-21 bib abs

L3   ANSWER 1 OF 21   MEDLINE on STN
AN   2007557753   MEDLINE
DN   PubMed ID: 17622580
TI   A mouse model for studying the interaction of bisdioxopiperazines with
     topoisomerase IIalpha in vivo.
AU   Grauslund Morten; Thougaard Annemette Vinding; Fuchtbauer Annette; Hofland
     Kenneth Francis; Hjorth Peter Hansen; Jensen Peter B; Sehested Maxwell;
     Fuchtbauer Ernst-Martin; Jensen Lars H
CS   Experimental Pathology Unit, Department of Pathology, Rigshospitalet afs.
     3731, Biocenter, Bygning 2, 3 sal., Ole Maaloes vej 5, DK-2100 Copenhagen
     O, Denmark.
SO   Molecular pharmacology, (2007 Oct) Vol. 72, No. 4, pp. 1003-14.
     Electronic Publication: 2007-07-10.
     Journal code: 0035623. ISSN: 0026-895X.
CY   United States

DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200711
ED Entered STN: 20 Sep 2007
Last Updated on STN: 8 Dec 2007
Entered Medline: 27 Nov 2007
AB The bisdioxopiperazines such as (+)-(S)-4,4'-propylenedi-2,6-piperazinedione (dexrazoxane; ICRF-187), 1,2-bis(3,5-dioxopiperazin-1-yl)ethane (ICRF-154), and 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione (ICRF-193) are agents that inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis products are strong iron chelator. The clinically approved analog ICRF-187 is a pharmacological modulator of topoisomerase II poisons such as etoposide in preclinical animal models. ICRF-187 is also used to protect against anthracycline-induced cardiomyopathy and has recently been approved as an antidote for alleviating tissue damage and necrosis after accidental anthracycline extravasation. This dual modality of bisdioxopiperazines, including ICRF-187, raises the question of whether their pharmacological in vivo effects are mediated through interaction with topoisomerase II or via their intracellular iron chelating activity. In an attempt to distinguish between these possibilities, we here present a transgenic mouse model aimed at identifying the contribution of topoisomerase IIalpha to the effects of bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in topoisomerase IIalpha, demonstrated previously to render the human ortholog of this enzyme highly resistant toward bisdioxopiperazines, was introduced at the TOP2A locus in mouse embryonic stem cells by targeted homologous recombination. These cells were used for the generation of transgenic TOP2A(Y165S/+) mice, which were demonstrated to be resistant toward the general toxicity of both ICRF-187 and ICRF-193. Hematological measurements indicate that this is most likely caused by a decreased ability of these agents to induce myelosuppression in TOP2A(Y165S/+) mice, highlighting the role of topoisomerase IIalpha in this process. The biological and pharmacological implications of these findings are discussed, and areas for further investigations are proposed.

L3 ANSWER 2 OF 21 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2008:312487 BIOSIS
DN PREV200800316670
TI A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase II alpha in vivo.
AU Grauslund, Morten; Thougaard, Annemette Vinding; Fuechtbauer, Annette; Hofland, Kenneth Francis; Hjorth, Peter Hansen; Jensen, Peter B.; Sehested, Maxwell; Fuechtbauer, Ernst-Martin; Jensen, Lars H. [Reprint Author]
CS Rigshosp, Dept Pathol, Expt Pathol Unit, Bioctr, Bygning 2,3 Sal,Ole Maaloes Vej 5, DK-2100 Copenhagen O, Denmark
lhj@topotarget.com
SO Molecular Pharmacology, (OCT 2007) Vol. 72, No. 4, pp. 1003-1014.
http:/www.molpharm.org.
CODEN: MOPMA3. ISSN: 0026-895X.
DT Article
LA English
ED Entered STN: 21 May 2008
Last Updated on STN: 21 May 2008
AB The bisdioxopiperazines such as (+)-(S)-4,4 '-propylenedi-2,6-piperazinedione (dexrazoxane; ICRF-187), 1,2-bis(3,5-dioxopiperazin1- yl) ethane (ICRF-154), and 4,4 '-(1,2-dimethyl-1,2-ethanediyl) bis-2,6-piperazinedione (ICRF-193) are agents that

inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis products are strong iron chelator. The clinically approved analog ICRF-187 is a pharmacological modulator of topoisomerase II poisons such as etoposide in preclinical animal models. ICRF- 187 is also used to protect against anthracyclineinduced cardiomyopathy and has recently been approved as an antidote for alleviating tissue damage and necrosis after accidental anthracycline extravasation. This dual modality of bisdioxopiperazines, including ICRF- 187, raises the question of whether their pharmacological in vivo effects are mediated through interaction with topoisomerase II or via their intracellular iron chelating activity. In an attempt to distinguish between these possibilities, we here present a transgenic mouse model aimed at identifying the contribution of topoisomerase II alpha to the effects of bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in topoisomerase II alpha, demonstrated previously to render the human ortholog of this enzyme highly resistant toward bisdioxopiperazines, was introduced at the TOP2A locus in mouse embryonic stem cells by targeted homologous recombination. These cells were used for the generation of transgenic TOP2A(Y165S/+) mice, which were demonstrated to be resistant toward the general toxicity of both ICRF-187 and ICRF-193. Hematological measurements indicate that this is most likely caused by a decreased ability of these agents to induce myelosuppression in TOP2A(Y165S/+) mice, highlighting the role of topoisomerase II alpha in this process. The biological and pharmacological implications of these findings are discussed, and areas for further investigations are proposed.

L3 ANSWER 3 OF 21 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2001:435706 BIOSIS
DN PREV200100435706
TI Topoisomerase II poison and
bis-dioxopiperazine derivative combination therapy.
AU Jensen, Peter Buhl [Inventor, Reprint author]; Sehested, Maxwell [Inventor]
CS Farum, Denmark
ASSIGNEE: Topo Target ApS, Copenhagen, Denmark
PI US 6265385 20010724
SO Official Gazette of the United States Patent and Trademark Office Patents, (July 24, 2001) Vol. 1248, No. 4. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 12 Sep 2001
Last Updated on STN: 22 Feb 2002
AB The present invention relates to a method for selectively killing tumor or metastatic cells within a defined compartment of the organism of a large mammal, in particular a human, said method comprising administering to a mammal an effective tumor--or metastasis-killing amount of a topoisomerase II poison except doxorubicin, and protecting non-tumorous tissue of the mammal against the toxic action of the topoisomerase II poison by administration of a bis-dioxypiperazine compound. In particular, the invention relates to a pharmaceutical kit for selectively killing tumor or metastatic cells within the central nervous system in a large mammal, in particular a human, said kit comprising: a) a dosage unit of a bis-dioxypiperazine and a pharmaceutically acceptable carrier, and b) a dosage unit of topoisomerase II poisons except doxorubicin and a pharmaceutically acceptable carrier.

L3 ANSWER 4 OF 21 BABS COPYRIGHT 2008 BEILSTEIN MDL on STN
AN 6710431 BABS

TI A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIα in vivo
AU Grauslund, Morten; Thougaard, Annemette Vinding; Fuechtbauer, Annette; Hofland, Kenneth Francis; Hjorth, Peter Hansen; Jensen, Peter B.; Sehested, Maxwell; Fuechtbauer, Ernst-Martin; Jensen, Lars H.
SO Mol. Pharmacol. (2007), 72(4), 1003 - 1014
CODEN: MOPMA3
DT Journal
AN 6710431 BABS
AB The bisdioxopiperazines such as (+)-(S)-4,4'-propylenedi-2,6-piperazinedione (dexrazoxane; ICRF-187), 1,2-bis(3,5-dioxopiperazin-1-yl)ethane (ICRF-154), and 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione (ICRF-193) are agents that inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis products are strong iron chelator. The clinically approved analog ICRF-187 is a pharmacological modulator of topoisomerase II poisons such as etoposide in preclinical animal models. ICRF-187 is also used to protect against anthracycline-induced cardiomyopathy and has recently been approved as an antidote for alleviating tissue damage and necrosis after accidental anthracycline extravasation. This dual modality of bisdioxopiperazines, including ICRF-187, raises the question of whether their pharmacological in vivo effects are mediated through interaction with topoisomerase II or via their intracellular iron chelating activity. In an attempt to distinguish between these possibilities, we here present a transgenic mouse model aimed at identifying the contribution of topoisomerase IIαto the effects of bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in topoisomerase IIα, demonstrated previously to render the human ortholog of this enzyme highly resistant toward bisdioxopiperazines, was introduced at the TOP2A locus in mouse embryonic stem cells by targeted homologous recombination. These cells were used for the generation of transgenic TOP2A Y165S/+ mice, which were demonstrated to be resistant toward the general toxicity of both ICRF-187 and ICRF-193. Hematological measurements indicate that this is most likely caused by a decreased ability of these agents to induce myelosuppression in TOP2AY165S/+ mice, highlighting the role of topoisomerase IIα in this process. The biological and pharmacological implications of these findings are discussed, and areas for further investigations are proposed.

L3 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1121923 CAPLUS
DN 147:479990
TI A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIα in vivo
AU Grauslund, Morten; Thougaard, Annemette Vinding; Fuchtbauer, Annette; Hofland, Kenneth Francjs; Hjorth, Peter Hansen; Jensen, Peter B.; Sehested, Maxwell; Fuchtbauer, Ernst-Martin; Jensen, Lars H.
CS Experimental Pathology Unit, Department of Pathology, Copenhagen University Hospital, Copenhagen, Den.
SO Molecular Pharmacology (2007), 72(4), 1003-1014
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
AB The bisdioxopiperazines such as (+)-(S)-4,4'-propylenedi-2,6-piperazinedione (dexrazoxane; ICRF-187), 1,2-bis(3,5-dioxopiperazin-1-yl)ethane (ICRF-154), and 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione (ICRF-193) are agents that inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis products are strong iron chelator. The clin. approved analog ICRF-187 is a pharmacol. modulator of topoisomerase II

poisons such as etoposide in preclin. animal models. ICRF-187 is also used to protect against anthracycline-induced cardiomyopathy and has recently been approved as an antidote for alleviating tissue damage and necrosis after accidental anthracycline extravasation. This dual modality of bisdioxopiperazines, including ICRF-187, raises the question of whether their pharmacol. in vivo effects are mediated through interaction with topoisomerase II or via their intracellular iron chelating activity. In an attempt to distinguish between these possibilities, the authors here present a transgenic mouse model aimed at identifying the contribution of topoisomerase IIα to the effects of bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in topoisomerase IIα, demonstrated previously to render the human ortholog of this enzyme highly resistant toward bisdioxopiperazines, was introduced at the TOP2A locus in mouse embryonic stem cells by targeted homologous recombination. These cells were used for the generation of transgenic TOP2AY165S/+ mice, which were demonstrated to be resistant toward the general toxicity of both ICRF-187 and ICRF-193. Hematol. measurements indicate that this is most likely caused by a decreased ability of these agents to induce myelosuppression in TOP2AY165S/+ mice, highlighting the role of topoisomerase IIα in this process. The biol. and pharmacol. implications of these findings are discussed, and areas for further investigations are proposed.

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1004605 CAPLUS
DN 143:279366
TI Cancer treatment with topoisomerase II inhibitor, a bis-dioxypiperazine and radiation
IN Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul; Thougaard, Annemette; Jensen, Peter Buhl
PA Topotarget A/S, Den.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084754	A2	20050915	WO 2005-IB670	20050302
	WO 2005084754	A3	20060526		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005219034	A1	20050915	AU 2005-219034	20050302
	CA 2557857	A1	20050915	CA 2005-2557857	20050302
	EP 1720612	A2	20061115	EP 2005-708755	20050302
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	JP 2007527428	T	20070927	JP 2007-501380	20050302
	US 20070185124	A1	20070809	US 2007-591847	20070109
PRAI	GB 2004-4675	A	20040302		

WO 2005-IB670 W 20050302

AB The present invention relates to a method of treatment of a tumor cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane, wherein said subject is further treated with radiation.

L3 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:556108 CAPLUS
DN 127:145175
OREF 127:27889a
TI Topoisomerase II poison and bis-dioxypiperazine derivative combination therapy
IN Jensen, Peter Buhl; Sehested, Maxwell
PA Jensen, Peter Buhl, Den.; Sehested, Maxwell
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9725044	A1	19970717	WO 1997-DK13	19970110
	W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2242406	A1	19970717	CA 1997-2242406	19970110
	AU 9713677	A	19970801	AU 1997-13677	19970110
	EP 874630	A1	19981104	EP 1997-900205	19970110
	EP 874630	B1	20030820		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 247468	T	20030915	AT 1997-900205	19970110
	PT 874630	T	20040130	PT 1997-900205	19970110
	ES 2205164	T3	20040501	ES 1997-900205	19970110
	US 6265385	B1	20010724	US 1999-101499	19990308
PRAI	DK 1996-22	A	19960111		
	US 1996-603105	A	19960220		
	WO 1997-DK13	W	19970110		

AB The present invention relates to a method for selectively killing tumor or metastatic cells within a defined compartment of the organism of a large mammal, in particular a human, said method comprising administering to a mammal an effective tumor- or metastasis-killing amount of a topoisomerase II poison except doxorubicin, and protecting non-tumorous tissue of the mammal against the toxic action of the topoisomerase II poison by administration of a bis-dioxypiperazine compound In particular, the invention relates to a pharmaceutical kit for selectively killing tumor or metastatic cells within the central nervous system of a large mammal, in particular a human, said kit comprising: a) a dosage unit of a bis-dioxypiperazine and a pharmaceutically acceptable carrier, and b) a dosage unit of topoisomerase II poisons except doxorubicin and a pharmaceutically acceptable carrier.

L3 ANSWER 8 OF 21 IFIPAT COPYRIGHT 2008 IFI on STN

AN 11535037 IFIPAT;IFIUDB;IFICDB
TI Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation
INF Hofland; Kenneth, Copenhagen, DK
Sehested; Maxwell, Copenhagen, DK
Kristjansen; Paul, Copenhagen, DK
Thougaard; Annenette, Copenhagen, DK
Jensen; Peter Buhl, Copenhagen, DK
IN Hofland Kenneth (DK); Jensen Peter Buhl (DK); Kristjansen Paul (DK); Sehested Maxwell (DK); Thougaard Annenette (DK)
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
PPA Topotarget A S DK (Probable)
AG NIXON & VANDERHYE, PC, 901 NORTH GLEBE ROAD, 11TH FLOOR, ARLINGTON, VA, 22203, US
PI US 20070185124 A1 20070809
AI US 2005-591847 20050302
WO 2005-IB670 20050302
20070109 PCT 371 date
20070109 PCT 102(e) date
PRAI GB 2004-46751 20040302
FI US 20070185124 20070809
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
ED Entered STN: 10 Aug 2007
Last Updated on STN: 13 Sep 2007
CLMN 10
AB The present invention relates to a method of treatment of a tumour cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison , e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane wherein said subject is further treated with radiation.
CLMN 10

L3 ANSWER 9 OF 21 IFIPAT COPYRIGHT 2008 IFI on STN
AN 03547524 IFIPAT;IFIUDB;IFICDB
TI TOPOISOMERASE II POISON AND BIS-DIOXOPIPERAZINE DERIVATIVE COMBINATION THERAPY; SELECTIVELY KILLING TUMOR OR METASTATIC CELLS WITHIN A DEFINED COMPARTMENT OF A HUMAN; TOPOISOMERASE II POISON IS ETOPOSIDE OR TENIPOSIDE AND WHERE SAID BIS-DIOXOPIPERAZINE IS (+)-1,2-BIS(3,5-DIOXOPIPERAZINYL-1-YL)PROPANE
INF Jensen; Peter Buhl, Farum, DK
Sehested; Maxwell, Kobenhavn O, DK
IN Jensen Peter Buhl (DK); Sehested Maxwell (DK)
PAF Topo Target ApS, Copenhagen, DK
PA Topo Target ApS DK (57956)
EXNAM Geist, Gary
EXNAM Crane, L. E
AG Cooper, Iver P.
PI US 6265385 B1 20010724
WO 9725044 19970717
AI US 1999-101499 19990308
WO 1997-DK13 19970110
19990308 PCT 371 date
19990308 PCT 102(e) date
XPD 10 Jan 2017
PRAI DK 1996-22 19960111
FI US 6265385 20010724
DT Utility; Reassigned

FS CHEMICAL
GRANTED
ED Entered STN: 26 Jul 2001
Last Updated on STN: 8 Jul 2002
MRN 011670 MFN: 0172
011670 0179
CLMN 54
GI 1 Drawing Sheet(s), 1 Figure(s).
AB The present invention relates to a method for selectively killing tumor or metastatic cells within a defined compartment of the organism of a large mammal, in particular a human, said method comprising administering to a mammal an effective tumor-or metastasis-killing amount of a topoisomerase II poison except doxorubicin,
and protecting non-tumorous tissue of the mammal against the toxic action of the topoisomerase II poison by
administration of a bis-dioxypiperazine compound. In
particular, the invention relates to a pharmaceutical kit for selectively killing tumor or metastatic cells within the central nervous system in a large mammal, in particular a human, said kit comprising: a) a dosage unit of a bis-dioxypiperazine and a pharmaceutically acceptable carrier, and b) a dosage unit of topoisomerase II
poisons except doxorubicin and a pharmaceutically acceptable carrier.
CLMN 54
GI 1 Drawing Sheet(s), 1 Figure(s).

L3 ANSWER 10 OF 21 SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN
AN 2007:1060925 SCISEARCH
GA The Genuine Article (R) Number: 211YZ
TI A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase II alpha in vivo
AU Grauslund, Morten; Thougaard, Annemette Vinding; Fuechtbauer, Annette; Hofland, Kenneth Francis; Hjorth, Peter Hansen; Jensen, Peter B.; Sehested, Maxwell; Fuechtbauer, Ernst-Martin; Jensen, Lars H. (Reprint)
CS Rigshosp, Dept Pathol, Expt Pathol Unit, Bioctr, Bygning 2, 3 Sal, Ole Maaloes Vej 5, DK-2100 Copenhagen O, Denmark (Reprint); Univ Copenhagen Hosp, Dept Pathol, Expt Pathol Unit, DK-2100 Copenhagen, Denmark; Topo Target AS, Copenhagen, Denmark; Univ Aarhus, Dept Mol Biol, Aarhus, Denmark; Univ Copenhagen Hosp, Finsen Ctr, Lab Expt Med Oncol, DK-2100 Copenhagen, Denmark
lhj@topotarget.com
CYA Denmark
SO MOLECULAR PHARMACOLOGY, (OCT 2007) Vol. 72, No. 4, pp. 1003-1014.
ISSN: 0026-895X.
PB AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA.
DT Article; Journal
LA English
REC Reference Count: 40
ED Entered STN: 18 Oct 2007
Last Updated on STN: 18 Oct 2007
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB The bisdioxopiperazines such as (+)-(S)-4,4 '-propylenedi-2,6-piperazinedione (dexrazoxane; ICRF-187), 1,2-bis(3,5-dioxopiperazin1- yl) ethane (ICRF-154), and 4,4 '-(1,2-dimethyl-1,2-ethanediyl) bis-2,6-piperazinedione (ICRF-193) are agents that inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis products are strong iron chelator. The clinically approved analog ICRF-187 is a pharmacological modulator of topoisomerase II
poisons such as etoposide in preclinical animal models. ICRF- 187

is also used to protect against anthracyclineinduced cardiomyopathy and has recently been approved as an antidote for alleviating tissue damage and necrosis after accidental anthracycline extravasation. This dual modality of bisdioxopiperazines, including ICRF- 187, raises the question of whether their pharmacological in vivo effects are mediated through interaction with topoisomerase II or via their intracellular iron chelating activity. In an attempt to distinguish between these possibilities, we here present a transgenic mouse model aimed at identifying the contribution of topoisomerase II alpha to the effects of bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in topoisomerase II alpha, demonstrated previously to render the human ortholog of this enzyme highly resistant toward bisdioxopiperazines, was introduced at the TOP2A locus in mouse embryonic stem cells by targeted homologous recombination. These cells were used for the generation of transgenic TOP2A(Y165S/+) mice, which were demonstrated to be resistant toward the general toxicity of both ICRF-187 and ICRF-193. Hematological measurements indicate that this is most likely caused by a decreased ability of these agents to induce myelosuppression in TOP2A(Y165S/+) mice, highlighting the role of topoisomerase II alpha in this process. The biological and pharmacological implications of these findings are discussed, and areas for further investigations are proposed.

L3 ANSWER 11 OF 21 USPATFULL on STN
AN 2007:224264 USPATFULL
TI SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS
IN Jensen, Peter Buhl, Farum, DENMARK
Sokilde, Birgitte, Vaerlose, DENMARK
Carstensen, Elisabeth Vang, Farum, DENMARK
Langer, Seppo W., Gentofte, DENMARK
Creighton, Andrew, London, UNITED KINGDOM
Sehested, Maxvell, Copenhagen, DENMARK
Jensen, Lars Hollund, Valby, DENMARK
PA TOPOTARGET A/S (non-U.S. corporation)
PI US 20070196360 A1 20070823
AI US 2006-557631 A1 20061108 (11)
RLI Continuation of Ser. No. US 2002-108979, filed on 29 Mar 2002, ABANDONED
PRAI DK 2001-522 20010329
US 2001-279459P 20010329 (60)
DT Utility
FS APPLICATION
LREP FOLEY AND LARDNER LLP, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007, US
CLMN Number of Claims: 3
ECL Exemplary Claim: 1-47
DRWN 11 Drawing Page(s)
LN.CNT 1838
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Maleimide and succinimide derivatives were found to be effective topoisomerase II catalytic inhibitors. Due to this property, the maleimide and succinimide derivatives were investigated for their use as cytostatic agents and thus in the treatment of cancer. The compounds of the invention can be used in combination treatments with other cytostatic agents, such as topoisomerase II poisons. The maleimide and succinimide derivatives, due to their effective topoisomerase II catalytic inhibitory activity, are also useful as extravasation agents, such as upon administration of a topoisomerase II poison.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 21 USPATFULL on STN
AN 2007:211316 USPATFULL
TI Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation
IN Hofland, Kenneth, Copenhagen, DENMARK
Sehested, Maxwell, Copenhagen, DENMARK
Kristjansen, Paul, Copenhagen, DENMARK
Thougaard, Annenette, Copenhagen, DENMARK
Jensen, Peter Buhl, Copenhagen, DENMARK
PI US 20070185124 A1 20070809
AI US 2005-591847 A1 20050302 (10)
WO 2005-IB670 20050302
20070109 PCT 371 date
PRAI GB 2004-4675 20040302
DT Utility
FS APPLICATION
LREP NIXON & VANDERHYE, PC, 901 NORTH GLEBE ROAD, 11TH FLOOR, ARLINGTON, VA, 22203, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method of treatment of a tumour cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane wherein said subject is further treated with radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 21 USPATFULL on STN
AN 2007:36275 USPATFULL
TI Screening method for identifying hsp90 modulators
IN Jenkins, John, Liverpool, UNITED KINGDOM
Greenhalf, William, Liverpool, UNITED KINGDOM
O'Connor, David Ian, Staffordshire, UNITED KINGDOM
PA University of Liverpool, Liverpool, UNITED KINGDOM, L69 3BX (non-U.S. corporation)
PI US 20070031815 A1 20070208
AI US 2004-554973 A1 20040428 (10)
WO 2004-GB1828 20040428
20051031 PCT 371 date
PRAI GB 2003-10017 20030501
DT Utility
FS APPLICATION
LREP DAVIS WRIGHT TREMAINE LLP, 865 FIGUEROA STREET, SUITE 2400, LOS ANGELES, CA, 90017-2566, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 962
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A screening method for identifying and/or analysing Hsp90 inhibitors and/or Hsp90 agonists comprises the steps of contacting a compound with at least two of yeast strains A-E wherein each yeast strain comprises expression vectors from which a pair of binding partners for a yeast two-hybrid assay are expressed. The binding partner pairs comprise: A: Hsp90-targeting protein; B: Hsp90-Hsp90; C: Hsp90-p23; D: Hsp90-E3 ligase; E: Hsp90-Client. Inhibition and/or promotion of dimerisation

between the binding partners is then measured.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 21 USPATFULL on STN
AN 2006:282242 USPATFULL
TI Alkylating agent combinations in the treatment of cancer
IN Gerson, Stanton L., Huntington Valley, OH, UNITED STATES
Liu, Lili, Northfield, OH, UNITED STATES
PI US 20060241186 A1 20061026
AI US 2003-505400 A1 20030219 (10)
WO 2003-US5032 20030219
20050622 PCT 371 date
RLI Continuation of Ser. No. US 2002-79049, filed on 19 Feb 2002, GRANTED, Pat. No. US 6635677 Continuation-in-part of Ser. No. US 1999-373693, filed on 13 Aug 1999, GRANTED, Pat. No. US 6465448
DT Utility
FS APPLICATION
LREP FISH & NEAVE IP GROUP, ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 2099
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This application provides compositions and methods useful in the treatment of certain cancers. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 21 USPATFULL on STN
AN 2003:45313 USPATFULL
TI Succinimide and maleimide derivatives and their use as topoisomerase II catalytic inhibitors
IN Jensen, Peter Buhl, Farum, DENMARK
Sokilde, Birgitte, Vaerlose, DENMARK
Carstensen, Elisabeth Vang, Farum, DENMARK
Langer, Seppo W., Gentofte, DENMARK
Creighton, Andrew, London, UNITED KINGDOM
Sehested, Maxvell, Copenhagen, DENMARK
Jensen, Lars Hollund, Valby, DENMARK
PA Topo Target ApS, Copenhagen, DENMARK (non-U.S. corporation)
PI US 20030032625 A1 20030213
AI US 2002-108979 A1 20020329 (10)
PRAI DK 2001-522 20010329
US 2001-279459P 20010329 (60)
DT Utility
FS APPLICATION
LREP BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 2174
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Maleimide and succinimide derivatives were found to be effective topoisomerase II catalytic inhibitors. Due to this property, the maleimide and succinimide derivatives were investigated for their use as

cytostatic agents and thus in the treatment of cancer. The compounds of the invention can be used in combination treatments with other cytostatic agents, such as topoisomerase II poisons. The maleimide and succinimide derivatives, due to their effective topoisomerase II catalytic inhibitory activity, are also useful as extravasation agents, such as upon administration of a topoisomerase II poison.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 21 USPATFULL on STN
AN 2002:186136 USPATFULL
TI Treatment of accidental extravasation of anthracyclines
IN Langer, Seppo W., Gentofte, DENMARK
Jensen, Peter B., Farum, DENMARK
Sehested, Maxwell, Copenhagen, DENMARK
PI US 20020099057 A1 20020725
US 6727253 B2 20040427
AI US 2001-893521 A1 20010629 (9)
RLI Continuation-in-part of Ser. No. WO 2000-DK107, filed on 13 Mar 2000, UNKNOWN
PRAI DK 1999-355 19990312
DT Utility
FS APPLICATION
LREP BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300, WASHINGTON, DC, 20001-5303
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 1375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method and a medicament for pharmacological treatment of accidental extravasation of topoisomerase II poisons such as anthracyclines. In particular, the invention relates to the use of a topo II catalytic nhibitor such as the bisdioxopiperazine ICRF-187 for the manufacture of a medicament for the treatment of an accidental extravasation of a topoisomerase II poison and a method for treatment of such extravasation of a topoisomerase poison such as the anthracyclines daunorubicin, doxorubicin, epirubicin, or idarubicin. In addition, the invention relates to a kit for such treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 21 USPATFULL on STN
AN 2001:116991 USPATFULL
TI Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy
IN Jensen, Peter Buhl, Farum, Denmark
Sehested, Maxwell, K.o slashed.benhavn .O slashed., Denmark
PA Topo Target ApS, Copenhagen, Denmark (non-U.S. corporation)
PI US 6265385 B1 20010724
WO 9725044 19970717
AI US 1999-101499 19990308 (9)
WO 1997-DK13 19970110
19990308 PCT 371 date
19990308 PCT 102(e) date
PRAI DK 1996-22 19960111
DT Utility
FS GRANTED

EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Crane, L. E.
LREP   Cooper, Iver P.
CLMN   Number of Claims: 54
ECL   Exemplary Claim: 1,12,43
DRWN   1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1373
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   The present invention relates to a method for selectively killing tumor or metastatic cells within a defined compartment of the organism of a large mammal, in particular a human, said method comprising administering to a mammal an effective tumor--or metastasis-killing amount of a topoisomerase II poison except doxorubicin, and protecting non-tumorous tissue of the mammal against the toxic action of the topoisomerase II poison by administration of a bis-dioxypiperazine compound. In particular, the invention relates to a pharmaceutical kit for selectively killing tumor or metastatic cells within the central nervous system in a large mammal, in particular a human, said kit comprising: a) a dosage unit of a bis-dioxypiperazine and a pharmaceutically acceptable carrier, and b) a dosage unit of topoisomerase II poisons except doxorubicin and a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3   ANSWER 18 OF 21 USPAT2 on STN
AN   2002:186136 USPAT2
TI   Treatment of accidental extravasation of anthracyclines
IN   Langer, Seppo W., Gentofte, DENMARK
       Jensen, Peter B., Farum, DENMARK
       Sehested, Maxwell, Copenhagen, DENMARK
PA   Antianthra APS, Farum, DENMARK (non-U.S. corporation)
PI   US 6727253   B2 20040427
AI   US 2001-893521   20010629 (9)
RLI   Continuation-in-part of Ser. No. WO 2000-DK107, filed on 13 Mar 2000
PRAI   DK 1999-355   19990312
DT   Utility
FS   GRANTED
EXNAM Primary Examiner: Spivack, Phyllis G.
LREP   Cooper, Iver P.
CLMN   Number of Claims: 31
ECL   Exemplary Claim: 1
DRWN   12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 1327
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   The present invention relates to a method for pharmacological treatment of accidental extravasation of topoisomerase II poisons, such as anthracyclines. In particular, the invention relates to the use of a topo II catalytic inhibitor, such as the bisdioxopiperazine ICRF-187, for the treatment of an accidental extravasation of a topoisomerase II poison . A method for treatment of such extravasation of a topoisomerase poison such as the anthracyclines, daunorubicin, doxorubicin, epirubicin, or idarubicin is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3   ANSWER 19 OF 21 WPINDEX COPYRIGHT 2008   THOMSON REUTERS on STN
AN   1997-372598 [34]   WPINDEX
DNC C1997-120018 [34]
TI   Selective killing of tumour or metastatic cells - using

topoisomerase II poison except doxorubicin and bis-dioxypiperazine compound to protect non-tumourous tissue

DC B03; B05

IN JENSEN P; JENSEN P B; LENSEN P B; SEHESTED M

PA (JENS-I) JENSEN P; (JENS-I) JENSEN P B; (SEHE-I) SEHESTED M; (TOPO-N) TOPO TARGET APS; (TOPO-N) TOPOTARGET APS

CYC 72

PIA WO 9725044 A1 19970717 (199734)* EN 53[1]
AU 9713677 A 19970801 (199748) EN
EP 874630 A1 19981104 (199848) EN
US 6265385 B1 20010724 (200146) EN
EP 874630 B1 20030820 (200356) EN
DE 69724228 E 20030925 (200371) DE
ES 2205164 T3 20040501 (200431) ES

ADT WO 9725044 A1 WO 1997-DK13 19970110; AU 9713677 A AU 1997-13677 19970110; DE 69724228 E DE 1997-69724228 19970110; EP 874630 A1 EP 1997-900205 19970110; EP 874630 B1 EP 1997-900205 19970110; DE 69724228 E EP 1997-900205 19970110; ES 2205164 T3 EP 1997-900205 19970110; AU 9713677 A WO 1997-DK13 19970110; EP 874630 A1 WO 1997-DK13 19970110; US 6265385 B1 WO 1997-DK13 19970110; EP 874630 B1 WO 1997-DK13 19970110; DE 69724228 E WO 1997-DK13 19970110; US 6265385 B1 US 1999-101499 19990308

FDT DE 69724228 E Based on EP 874630 A; ES 2205164 T3 Based on EP 874630 A; AU 9713677 A Based on WO 9725044 A; EP 874630 A1 Based on WO 9725044 A; US 6265385 B1 Based on WO 9725044 A; EP 874630 B1 Based on WO 9725044 A; DE 69724228 E Based on WO 9725044 A

PRAI US 1996-603105 19960220
DK 1996-22 19960111

AN 1997-372598 [34] WPINDEX

AB WO 1997025044 A1 UPAB: 20050703
Method for selectively killing tumour or metastatic cells within a compartment of the organism of a large mammal, in particular a human, comprises administering a topoisomerase II poison (T II P) except doxorubicin, and protecting non-tumourous tissue of the mammal against the toxic action of the T II P by administration of a bis-dioxypiperazine compound (BDC).
Also claimed is a kit for selectively killing tumour or metastatic cells within the central nervous system (CNS) of a large mammal, particularly a human, comprising:
(a) a dosage unit of a BDC and a carrier, and
(b) a dosage unit of T II P except doxorubicin and a carrier.
USE - The method can be used for selectively killing tumour or metastatic cells, particularly in the CNS of humans (all claimed).
ADVANTAGE - Using the method the normal tissue is protected from the poison by the bis-dioxypiperazine whereby the malignant conditions can be treated with higher dosages of the T II P and side effects are reduced.

Member(0003)

ABEQ EP 874630 A1 UPAB 20050703
Method for selectively killing tumour or metastatic cells within a compartment of the organism of a large mammal, in particular a human, comprises administering a topoisomerase II poison (T II P) except doxorubicin, and protecting non-tumourous tissue of the mammal against the toxic action of the T II P by administration of a bis-dioxypiperazine compound (BDC).
Also claimed is a kit for selectively killing tumour or metastatic cells within the central nervous system (CNS) of a large mammal, particularly a human, comprising:
(a) a dosage unit of a BDC and a carrier, and
(b) a dosage unit of T II P except doxorubicin and a carrier.
USE - The method can be used for selectively killing tumour or

metastatic cells, particularly in the CNS of humans (all claimed).
ADVANTAGE - Using the method the normal tissue is protected from the poison by the bis-dioxypiperazine whereby the malignant conditions can be treated with higher dosages of the T II P and side effects are reduced.

Member(0004)
ABEQ US 6265385 B1 UPAB 20050703
Method for selectively killing tumour or metastatic cells within a compartment of the organism of a large mammal, in particular a human, comprises administering a topoisomerase II poison (T II P) except doxorubicin, and protecting non-tumourous tissue of the mammal against the toxic action of the T II P by administration of a bis-dioxypiperazine compound (BDC).
Also claimed is a kit for selectively killing tumour or metastatic cells within the central nervous system (CNS) of a large mammal, particularly a human, comprising:
(a) a dosage unit of a BDC and a carrier, and
(b) a dosage unit of T II P except doxorubicin and a carrier.
USE - The method can be used for selectively killing tumour or metastatic cells, particularly in the CNS of humans (all claimed).
ADVANTAGE - Using the method the normal tissue is protected from the poison by the bis-dioxypiperazine whereby the malignant conditions can be treated with higher dosages of the T II P and side effects are reduced.

L3 ANSWER 20 OF 21 EMBASE
AN 2008097296 EMBASE
TI Mutagenicity of some topoisomerase II-interactive agents.
AU Attia, Sabry M. (correspondence)
CS Department of Pharmacology, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia. attiasm@yahoo.com
SO Saudi Pharmaceutical Journal, (Jan 2008) Vol. 16, No. 1, pp. 1-24.
Refs: 207
ISSN: 1319-0164 CODEN: SPJOEM
CY Saudi Arabia
DT Journal; General Review; (Review)
FS 016 Cancer
017 Public Health, Social Medicine and Epidemiology
022 Human Genetics
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English; Arabic
ED Entered STN: 4 Apr 2008
Last Updated on STN: 4 Apr 2008
AB Among the anticancer drugs currently used in the treatment of human malignancies, as well as several new series of drugs under development, are targeted at topoisomerase II enzymes. Besides of inducing cell death due to both 'mitotic catastrophe' and the induction of apoptosis, topoisomerase-II-targeted drugs can increase the frequency of cells bearing mutations. These cells can develop resistance to the therapeutic agents or may lead to the development of secondary tumours and abnormal reproductive outcomes. This review focuses on the mutagenic properties of the topoisomerase II poisons etoposide, doxorubicin and amsacrine, which are front-line therapies for a variety of malignancies, and genistein, which is prominent in soybean foods and is believed to be a chemopreventative agent that contributes to the low incidence of specific cancers among Asian populations. In addition, the topoisomerase II catalytic inhibitor merbarone that is in clinical trials

as an anticancer agent will be discussed. It clear from the present review that, the topoisomerase II-interactive anticancer agents appear to be mutagenic. Therefore, the clinical use of these mutagenic drugs must be weighed against the risks of secondary malignancies in cured patients and persistent genetic damage of their potential offspring.

L3 ANSWER 21 OF 21 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
AN 2007472968 EMBASE
TI A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIα in vivo.
AU Grauslund, Morten; Sehested, Maxwell; Jensen, Lars H., Dr. (correspondence)
CS Experimental Pathology Unit, Department of Pathology, Copenhagen University Hospital, Copenhagen, Denmark. lhj@topotarget.com
AU Grauslund, Morten; Thougaard, Annemette Vinding; Hofland, Kenneth Francis; Jensen, Peter B.; Sehested, Maxwell; Jensen, Lars H., Dr. (correspondence)
CS TopoTarget A/S, Copenhagen, Denmark. lhj@topotarget.com
AU Fuchtbauer, Annette; Hjorth, Peter Hansen; Fuchtbauer, Ernst-Martin
CS Department of Molecular Biology, University of Aarhus, Aarhus, Denmark.
AU Jensen, Peter B.
CS Laboratory for Experimental Medical Oncology, Finsen Center, Copenhagen University Hospital, Copenhagen, Denmark.
AU Jensen, Lars H., Dr. (correspondence)
CS Department of Pathology, Rigshospitalet Afs. 3731, Biocenter, Bygning 2, 3 sal., Ole Maales vej 5, DK-2100 Copenhagen O, Denmark. lhj@topotarget.com
SO Molecular Pharmacology, (Oct 2007) Vol. 72, No. 4, pp. 1003-1014.
Refs: 40
ISSN: 0026-895X E-ISSN: 1521-0111 CODEN: MOPMA3
CY United States
DT Journal; Article
FS 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
052 Toxicology
LA English
SL English
ED Entered STN: 11 Oct 2007
Last Updated on STN: 11 Oct 2007
AB The bisdioxopiperazines such as (+)-(S)-4,4'-propylenedi-2,6-piperazinedione (dexrazoxane; ICRF-187), 1,2-bis(3,5-dioxopiperazin-1-yl)ethane (ICRF-154), and 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione (ICRF-193) are agents that inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis products are strong iron chelator. The clinically approved analog ICRF-187 is a pharmacological modulator of topoisomerase II poisons such as etoposide in preclinical animal models. ICRF-187 is also used to protect against anthracycline-induced cardiomyopathy and has recently been approved as an antidote for alleviating tissue damage and necrosis after accidental anthracycline extravasation. This dual modality of bisdioxopiperazines, including ICRF-187, raises the question of whether their pharmacological in vivo effects are mediated through interaction with topoisomerase II or via their intracellular iron chelating activity. In an attempt to distinguish between these possibilities, we here present a transgenic mouse model aimed at identifying the contribution of topoisomerase IIαto the effects of bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in topoisomerase IIα, demonstrated previously to render the human ortholog of this enzyme highly resistant toward bisdioxopiperazines, was introduced at the TOP2A locus in mouse embryonic stem cells by targeted homologous recombination. These cells were used for the generation of transgenic TOP2A (Y165S/+) mice, which were demonstrated to be resistant

toward the general toxicity of both ICRF-187 and ICRF-193. Hematological measurements indicate that this is most likely caused by a decreased ability of these agents to induce myelosuppression in TOP2A(Y165S/+) mice, highlighting the role of topoisomerase IIα in this process. The biological and pharmacological implications of these findings are discussed, and areas for further investigations are proposed. Copyright .COPYRGT. 2007 The American Society for Pharmacology and Experimental Therapeutics.

```
=> s piperazinedione(w)radiation
L4           1 PIPERAZINEDIONE(W) RADIATION

=> dis l4 bib abs

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   1977:113324  CAPLUS
DN   86:113324
OREF 86:17827a,17830a
TI   An ENDOR study of the δ proton hyperfine interaction in x-ray
     damaged 2,5-piperazinedione
AU   Helms, H. A., Jr.; Miyagawa, Ichiro
CS   Dep. Phys. Astron., Univ. Alabama, University, AL, USA
SO   Journal of Chemical Physics (1976), 65(9), 3493-4
     CODEN: JCPSA6; ISSN: 0021-9606
DT   Journal
LA   English
AB   ENDOR studies of x-ray irradiated crystals of 2,5-piperazinedione were
     conducted. The structure of the primary radical reported in the previous
     ESR studies was confirmed, but anal. of the δ proton hfs tensors
     showed that neither of the previously proposed models for hfs of the
     δ proton is correct. The present results indicate that practically
     all of the spin d. must be in the vicinity of the α C.


=> s piperazinedione
L5        5385 PIPERAZINEDIONE

=> s l5 and radiation
L6         786 L5 AND RADIATION

=> s l6 and (anti(a)tumor)
L7         455 L6 AND (ANTI(A) TUMOR)

=> s l7 and toxicity
L8         433 L7 AND TOXICITY

=> s l8 and bis
L9         394 L8 AND BIS

=> s (bis and ethanediyl)
L10       6550 (BIS AND ETHANEDIYL)

=> s l8 and (bis and ethanediyl)
L11         67 L8 AND (BIS AND ETHANEDIYL)

=> s l11 and ionizing
L12         59 L11 AND IONIZING

=> dis l12 1-59 bib abs
```

L12 ANSWER 1 OF 59 USPATFULL on STN
AN 2008:152188 USPATFULL
TI Conformationally Constrained Smac Mimetics And The Uses Thereof
IN Wang, Shaomeng, Saline, MI, UNITED STATES
Sun, Haiying, Ann Arbor, MI, UNITED STATES
Nikolovksa-Coleska, Zaneta, Ann Arbor, MI, UNITED STATES
Yang, Chao-Yie, Ann Arbor, MI, UNITED STATES
Xu, Liang, Ann Arbor, MI, UNITED STATES
Saito, Naoyuki G., East Amherst, NY, UNITED STATES
Chen, Jianyong, Ann Arbor, MI, UNITED STATES
PI US 20080132485 A1 20080605
AI US 2005-632079 A1 20050711 (11)
WO 2005-US24530 20050711
20080220 PCT 371 date
PRAI US 2004-586575P 20040709 (60)
DT Utility
FS APPLICATION
LREP MEDLEN & CARROLL, LLP, 101 HOWARD STREET, SUITE 350, SAN FRANCISCO, CA, 94105, US
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 35 Drawing Page(s)
LN.CNT 2751
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 59 USPATFULL on STN
AN 2008:103430 USPATFULL
TI Bivalent SMAC mimetics and the uses thereof
IN Wang, Shaomeng, Saline, MI, UNITED STATES
Sun, Haiying, Ann Arbor, MI, UNITED STATES
Qin, Dongguang, Ann Arbor, MI, UNITED STATES
Nikolovska-Coleska, Zaneta, Ann Arbor, MI, UNITED STATES
Lu, Jianfeng, Ann Arbor, MI, UNITED STATES
Qiu, Su, Ann Arbor, MI, UNITED STATES
Peng, Yuefeng, Ann Arbor, MI, UNITED STATES
PA Regents of the University of Michigan, Ann Arbor, MI, UNITED STATES (U.S. corporation)
PI US 20080089896 A1 20080417
AI US 2007-800220 A1 20070504 (11)
PRAI US 2007-923415P 20070413 (60)
US 2006-798018P 20060505 (60)
DT Utility
FS APPLICATION
LREP MEDLEN & CARROLL, LLP, 101 HOWARD STREET, SUITE 350, SAN FRANCISCO, CA, 94105, US
CLMN Number of Claims: 61
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 3298
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 59 USPATFULL on STN
AN 2006:328918 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20060282123 A1 20061214
AI US 2004-6910 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2264
DRWN 32 Drawing Page(s)
LN.CNT 14774
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L12 ANSWER 4 OF 59 USPATFULL on STN
AN 2006:174046 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20060147492 A1 20060706
AI US 2006-343809 A1 20060131 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 56233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 59 USPATFULL on STN
AN 2005:241661 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050209666 A1 20050922
AI US 2004-6885 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-630
DRWN 32 Drawing Page(s)
LN.CNT 14772
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 59 USPATFULL on STN
AN 2005:241660 USPATFULL
TI Electrical devices and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050209665 A1 20050922
AI US 2004-998351 A1 20041126 (10)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-11691
DRWN 32 Drawing Page(s)
LN.CNT 14777
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L12 ANSWER 7 OF 59 USPATFULL on STN
AN 2005:241659 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050209664 A1 20050922
AI US 2004-998349 A1 20041126 (10)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586471P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1377
DRWN 32 Drawing Page(s)
LN.CNT 14786
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation

devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L12 ANSWER 8 OF 59 USPATFULL on STN
AN 2005:240095 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050208095 A1 20050922
AI US 2004-996354 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 34089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 59 USPATFULL on STN
AN 2005:234693 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050203635 A1 20050915
AI US 2004-6909 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 76
ECL Exemplary Claim: 1-3038
DRWN 32 Drawing Page(s)
LN.CNT 12596
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 59 USPATFULL on STN
AN 2005:226572 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050196421 A1 20050908
AI US 2004-1417 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 100
ECL Exemplary Claim: 1-7300
DRWN 32 Drawing Page(s)
LN.CNT 34222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 59 USPATFULL on STN
AN 2005:221910 USPATFULL

TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050192647 A1 20050901
AI US 2004-6898 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1992
DRWN 32 Drawing Page(s)
LN.CNT 14794
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L12 ANSWER 12 OF 59 USPATFULL on STN
AN 2005:220596 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050191331 A1 20050901
AI US 2004-1419 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-2104
DRWN 28 Drawing Page(s)
LN.CNT 56419

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 13 OF 59 USPATFULL on STN
AN 2005:215962 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050187639 A1 20050825
AI US 2004-6892 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1-3470
DRWN 32 Drawing Page(s)
LN.CNT 12657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 14 OF 59 USPATFULL on STN
AN 2005:215923 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050187600 A1 20050825
AI US 2004-998350 A1 20041126 (10)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-3352
DRWN 32 Drawing Page(s)
LN.CNT 14781
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L12 ANSWER 15 OF 59 USPATFULL on STN
AN 2005:215464 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050187140 A1 20050825
AI US 2004-408 A1 20041129 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2004-611077P 20040917 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 103
ECL Exemplary Claim: 1-5846
DRWN 32 Drawing Page(s)
LN.CNT 34103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 16 OF 59 USPATFULL on STN
AN 2005:214574 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050186246 A1 20050825
AI US 2004-6883 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1-2606
DRWN 32 Drawing Page(s)
LN.CNT 12658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 17 OF 59 USPATFULL on STN
AN 2005:214573 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050186245 A1 20050825
AI US 2004-6880 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2785
DRWN 32 Drawing Page(s)
LN.CNT 15059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 18 OF 59 USPATFULL on STN
AN 2005:214572 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050186244 A1 20050825
AI US 2004-1790 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 103
ECL Exemplary Claim: 1-8540
DRWN 32 Drawing Page(s)
LN.CNT 34060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 19 OF 59 USPATFULL on STN
AN 2005:214567 USPATFULL

TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050186239 A1 20050825
AI US 2004-6897 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-3058
DRWN 32 Drawing Page(s)
LN.CNT 15050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 20 OF 59 USPATFULL on STN
AN 2005:212068 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050183731 A1 20050825
AI US 2004-6908 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 52
ECL Exemplary Claim: 1-8061
DRWN 32 Drawing Page(s)
LN.CNT 34032
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L12 ANSWER 21 OF 59 USPATFULL on STN
AN 2005:212065 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050183728 A1 20050825
AI US 2004-7836 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-3411
DRWN 28 Drawing Page(s)
LN.CNT 56413
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L12 ANSWER 22 OF 59 USPATFULL on STN
AN 2005:210011 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182496 A1 20050818
AI US 2004-6906 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 76
ECL Exemplary Claim: 1-3902
DRWN 32 Drawing Page(s)
LN.CNT 12588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 23 OF 59 USPATFULL on STN
AN 2005:209984 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050182469 A1 20050818
AI US 2004-7837 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 120
ECL Exemplary Claim: 1-2803
DRWN 32 Drawing Page(s)
LN.CNT 14838
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation

devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 24 OF 59 USPATFULL on STN
AN 2005:209983 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182468 A1 20050818
AI US 2004-6891 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1720
DRWN 32 Drawing Page(s)
LN.CNT 14768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 25 OF 59 USPATFULL on STN
AN 2005:209982 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182467 A1 20050818
AI US 2004-6884 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1168
DRWN 32 Drawing Page(s)
LN.CNT 14785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 26 OF 59 USPATFULL on STN
AN 2005:209978 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050182463 A1 20050818
AI US 2004-1788 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 125
ECL Exemplary Claim: 1-8059
DRWN 32 Drawing Page(s)
LN.CNT 34070
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L12 ANSWER 27 OF 59 USPATFULL on STN
AN 2005:209965 USPATFULL

TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182450 A1 20050818
AI US 2004-6890 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-349
DRWN 32 Drawing Page(s)
LN.CNT 14792
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L12 ANSWER 28 OF 59 USPATFULL on STN
AN 2005:209494 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181977 A1 20050818
AI US 2004-986231 A1 20041110 (10)
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 182
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 56396
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 29 OF 59 USPATFULL on STN
AN 2005:208533 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181011 A1 20050818
AI US 2004-1792 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 177
ECL Exemplary Claim: 1-4994
DRWN 28 Drawing Page(s)
LN.CNT 56421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 30 OF 59 USPATFULL on STN
AN   2005:208532 USPATFULL
TI   Implantable sensors and implantable pumps and anti-scarring agents
IN   Hunter, William L., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
PA   Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI   US 20050181010   A1 20050818
AI   US 2004-1789   A1 20041201 (11)
RLI   Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING
       Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,
       PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov
       2004, PENDING
PRAI   US 2004-586861P   20040709 (60)
       US 2004-578471P   20040609 (60)
       US 2003-526541P   20031203 (60)
       US 2003-525226P   20031124 (60)
       US 2003-523908P   20031120 (60)
       US 2003-524023P   20031120 (60)
DT   Utility
FS   APPLICATION
LREP   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
       6300, SEATTLE, WA, 98104-7092, US
CLMN   Number of Claims: 109
ECL   Exemplary Claim: 1-296
DRWN   32 Drawing Page(s)
LN.CNT 15014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB   Pumps and sensors for contact with tissue are used in combination with
       an anti-scarring agent (e.g., a cell cycle inhibitor) in order to
       inhibit scarring that may otherwise occur when the pumps and sensors are
       implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 31 OF 59 USPATFULL on STN
AN   2005:208531 USPATFULL
TI   Implantable sensors and implantable pumps and anti-scarring agents
IN   Hunter, William L., Vancouver, CANADA
       Gravett, David M., Vancouver, CANADA
       Toleikis, Philip M., Vancouver, CANADA
       Maiti, Arpita, Vancouver, CANADA
PA   Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI   US 20050181009   A1 20050818
AI   US 2004-1787   A1 20041201 (11)
RLI   Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING
       Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,
       PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov
       2004, PENDING
PRAI   US 2004-586861P   20040709 (60)
       US 2004-578471P   20040609 (60)
       US 2003-526541P   20031203 (60)
       US 2003-525226P   20031124 (60)
       US 2003-523908P   20031120 (60)
       US 2003-524023P   20031120 (60)
DT   Utility
FS   APPLICATION
LREP   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
       6300, SEATTLE, WA, 98104-7092, US
CLMN   Number of Claims: 110

ECL Exemplary Claim: 1-570
DRWN 32 Drawing Page(s)
LN.CNT 15035
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 32 OF 59 USPATFULL on STN
AN 2005:208530 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181008 A1 20050818
AI US 2004-1786 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-4736
DRWN 28 Drawing Page(s)
LN.CNT 56377
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 33 OF 59 USPATFULL on STN
AN 2005:208529 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181007 A1 20050818
AI US 2004-1415 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 126
ECL Exemplary Claim: 1-444
DRWN 32 Drawing Page(s)
LN.CNT 12675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 34 OF 59 USPATFULL on STN
AN 2005:208527 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050181005 A1 20050818
AI US 2004-6901 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2510
DRWN 32 Drawing Page(s)
LN.CNT 15035
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 35 OF 59 USPATFULL on STN
AN 2005:205930 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050178396 A1 20050818
AI US 2004-6905 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1-8063
DRWN 32 Drawing Page(s)
LN.CNT 33965
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L12 ANSWER 36 OF 59 USPATFULL on STN
AN 2005:205929 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050178395 A1 20050818
AI US 2004-6900 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 58
ECL Exemplary Claim: 1-7302
DRWN 32 Drawing Page(s)
LN.CNT 34043
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L12 ANSWER 37 OF 59 USPATFULL on STN
AN 2005:203799 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, CH (non-U.S. corporation)
PI US 20050177225 A1 20050811
AI US 2004-6895 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 173
ECL Exemplary Claim: 1-11788
DRWN 28 Drawing Page(s)
LN.CNT 56371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens,

an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 38 OF 59 USPATFULL on STN
AN 2005:202285 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050175703 A1 20050811
AI US 2004-6888 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1-7576
DRWN 32 Drawing Page(s)
LN.CNT 33992
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 39 OF 59 USPATFULL on STN
AN 2005:202247 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050175665 A1 20050811
AI US 2004-6896 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING

Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1-7822
DRWN 32 Drawing Page(s)
LN.CNT 33978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 40 OF 59 USPATFULL on STN
AN 2005:202246 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050175664 A1 20050811
AI US 2004-4672 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 109
ECL Exemplary Claim: 1-851
DRWN 32 Drawing Page(s)
LN.CNT 15038
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 41 OF 59 USPATFULL on STN
AN 2005:202245 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050175663 A1 20050811
AI US 2004-1791 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 180
ECL Exemplary Claim: 1-3944
DRWN 28 Drawing Page(s)
LN.CNT 56451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 42 OF 59 USPATFULL on STN
AN 2005:195820 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050169961 A1 20050804
AI US 2004-4675 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 118
ECL Exemplary Claim: 1-1941
DRWN 32 Drawing Page(s)
LN.CNT 15063
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 43 OF 59 USPATFULL on STN
AN 2005:195819 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050169960 A1 20050804
AI US 2004-4671 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 110
ECL Exemplary Claim: 1-3328
DRWN 32 Drawing Page(s)
LN.CNT 15057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 44 OF 59 USPATFULL on STN
AN 2005:190568 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)
PI US 20050165488 A1 20050728
AI US 2004-6912 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 176
ECL Exemplary Claim: 1-3153
DRWN 28 Drawing Page(s)
LN.CNT 56407
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L12 ANSWER 45 OF 59 USPATFULL on STN
AN 2005:182973 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050158356 A1 20050721
AI US 2004-996352 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 117
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 15058
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 46 OF 59 USPATFULL on STN
AN 2005:178293 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vacouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050154374 A1 20050714
AI US 2004-6882 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2240
DRWN 32 Drawing Page(s)
LN.CNT 15052
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 47 OF 59 USPATFULL on STN
AN 2005:176868 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152948 A1 20050714
AI US 2004-7838 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-2174
DRWN 32 Drawing Page(s)
LN.CNT 12627
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 48 OF 59 USPATFULL on STN
AN 2005:176867 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152947 A1 20050714
AI US 2004-6903 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-1742
DRWN 32 Drawing Page(s)
LN.CNT 12637
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 49 OF 59 USPATFULL on STN

AN 2005:176866 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152946 A1 20050714
AI US 2004-6894 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1126
DRWN 32 Drawing Page(s)
LN.CNT 15056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 50 OF 59 USPATFULL on STN
AN 2005:176865 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152945 A1 20050714
AI US 2004-6887 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-1310

DRWN 32 Drawing Page(s)
LN.CNT 12592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 51 OF 59 USPATFULL on STN
AN 2005:176864 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152944 A1 20050714
AI US 2004-6881 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-878
DRWN 32 Drawing Page(s)
LN.CNT 12628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 52 OF 59 USPATFULL on STN
AN 2005:176861 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152941 A1 20050714
AI US 2004-996353 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 132
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 12685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 53 OF 59 USPATFULL on STN
AN 2005:172409 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050149158 A1 20050707
AI US 2004-409 A1 20041129 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-274
DRWN 28 Drawing Page(s)
LN.CNT 56404
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal

implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 54 OF 59 USPATFULL on STN
AN 2005:172408 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050149157 A1 20050707
AI US 2004-996355 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 111
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 14769
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 55 OF 59 USPATFULL on STN
AN 2005:172331 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050149080 A1 20050707
AI US 2004-1418 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility

FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-806
DRWN 28 Drawing Page(s)
LN.CNT 56418
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L12 ANSWER 56 OF 59 USPATFULL on STN
AN 2005:164738 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050142162 A1 20050630
AI US 2004-1416 A1 20041201 (11)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-524023P 20031120 (60)
US 2003-523908P 20031120 (60)
US 2003-525226P 20031124 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 117
ECL Exemplary Claim: 1-4334
DRWN 32 Drawing Page(s)
LN.CNT 12679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 57 OF 59 USPATFULL on STN
AN 2004:328492 USPATFULL
TI Anastomotic connector devices
IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20040260318 A1 20041223
AI US 2004-853023 A1 20040524 (10)
PRAI US 2003-473185P 20030523 (60)
US 2003-523908P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 117
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 6906
AB Anastomotic connector devices are provided which release a therapeutic agent. The therapeutic agent may be an anti-scarring agent that inhibits stenosis caused by the presence of the anastomotic connector device.

L12 ANSWER 58 OF 59 USPATFULL on STN
AN 2004:274400 USPATFULL
TI Small molecule antagonists of BCL-2 family proteins
IN Wang, Shaomeng, Saline, MI, UNITED STATES
Yang, Dajun, Rockville, MD, UNITED STATES
PA The Regents of the University of Michigan, Ann Arbor, MI (U.S. corporation)
Georgetown University, Washington, DC (U.S. corporation)
PI US 20040214902 A1 20041028
AI US 2003-729156 A1 20031205 (10)
RLI Continuation-in-part of Ser. No. US 2002-158769, filed on 30 May 2002, ABANDONED Continuation-in-part of Ser. No. WO 2002-US17206, filed on 30 May 2002, PENDING
PRAI US 2001-293983P 20010530 (60)
DT Utility
FS APPLICATION
LREP David A. Casimir, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 55 Drawing Page(s)
LN.CNT 8211
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds as antagonists of the anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2, Bcl-X.sub.L, and the like). The present invention also provides compositions comprising gossypol compounds and optionally one or more additional therapeutic agents (e.g., anticancer/chemotherapeutic agents). The present invention also provides methods for treating diseases and pathologies (e.g., neoplastic diseases) comprising administering a composition comprising gossypol compounds and optionally one or more additional therapeutic agents (e.g., anticancer/chemotherapeutic agents) and/or techniques (e.g., radiation therapies, surgical interventions, and the like) to a

subject or in vitro cells, tissues, and organs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 59 OF 59 USPATFULL on STN
AN 90:79881 USPATFULL
TI Stable lyophilized form of (S)-(+)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione and solutions thereof
IN Palepu, Nagesh R., Franklin County, OH, United States
Martin, Joyce W., Franklin County, OH, United States
PA Erbamont Inc., Dublin, OH, United States (U.S. corporation)
PI US 4963551 19901016
AI US 1990-463844 19900112 (7)
RLI Continuation of Ser. No. US 1987-136036, filed on 21 Dec 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Bell, Mark L.; Assistant Examiner: Brunsman, David M.
LREP Thompson, Hine and Flory
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 378
AB The present invention is directed to a stable, rapidly soluble lyophilized injectable composition containing up to about 6% moisture and capable of being stored at room temperature comprising the hydrochloric or sulfate salt of a compound selected from the group consisting of (S)-(+)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione and (R)-(-)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione; wherein said lyophilized composition is prepared from a bulk solution comprising from about 25 mg/mL to about 40 mg/mL of said compound dissolved in a hydrochloric acid or sulfuric acid; wherein the pH of said bulk solution is from about 1.0 to about 2.0. The invention is further directed to an isotonic solution which is formed upon reconstitution of the lyophilizate of the invention with a pharmaceutically acceptable diluent.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	313.09	313.30
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

FILE 'CAPLUS' ENTERED AT 17:12:08 ON 15 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Aug 2008 VOL 149 ISS 8
FILE LAST UPDATED: 14 Aug 2008 (20080814/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s Hofland Kenneth/AU
L13 2 HOFLAND KENNETH/AU

=> dis l13 1-2 bib abs

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1004605 CAPLUS
DN 143:279366
TI Cancer treatment with topoisomerase II inhibitor, a bis-dioxypiperazine and radiation
IN Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul; Thougaard, Annemette; Jensen, Peter Buhl
PA Topotarget A/S, Den.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084754	A2	20050915	WO 2005-IB670	20050302
	WO 2005084754	A3	20060526		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005219034	A1	20050915	AU 2005-219034	20050302
	CA 2557857	A1	20050915	CA 2005-2557857	20050302
	EP 1720612	A2	20061115	EP 2005-708755	20050302
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	JP 2007527428	T	20070927	JP 2007-501380	20050302
	US 20070185124	A1	20070809	US 2007-591847	20070109
PRAI	GB 2004-4675	A	20040302		
	WO 2005-IB670	W	20050302		

AB The present invention relates to a method of treatment of a tumor cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in

combination with a bis-dioxypiperazine, e.g. dexrazoxane, wherein said subject is further treated with radiation.

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:307970 CAPLUS
DN 133:187729
TI Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex
AU Hofland, Kenneth; Petersen, Birgit O.; Falck, Jacob; Helin, Kristian; Jensen, Peter B.; Sehested, Maxwell
CS Laboratory and Finsen Centres, Rigshospitalet, Copenhagen, DK-2100, Den.
SO Clinical Cancer Research (2000), 6(4), 1488-1497
CODEN: CCREF4; ISSN: 1078-0432
PB American Association for Cancer Research
DT Journal
LA English
AB The transcription factor complex E2F-1/DP-1 regulates the G1-to-S-phase transition and was associated with sensitivity to the S-phase-specific anticancer agents camptothecin and etoposide, which poison DNA topoisomerase I and II, resp. To investigate the relationship between E2F-1 and drug sensitivity in detail, the authors established human osteosarcoma U-2OS-TA cells expressing full-length E2F-1/DP-1 under the control of a tetracycline-responsive promoter, designated UE1DP-1 cells. Topoisomerase I levels and activity as well as the number of camptothecin-induced DNA single- and double-strand breaks were unchanged in UE1DP-1/tc- cells with > 10-fold E2F-1/DP-1 overexpression. However, UE1DP-1/tc- cells were hypersensitive to camptothecin in both a clonogenic assay and 4 different apoptotic assays. This indicates that camptothecin-induced toxicity in this model is due to the activation of an E2F-1/DP-1-induced post-DNA damage pathway rather than an increase in the number of replication forks caused by the S-phase initiation. In contrast, topoisomerase IIα levels (but not topoisomerase IIβ levels), together with topoisomerase IIα promoter activity, increased 2-3-fold in UE1DP-1/tc- cells. Furthermore, the number of etoposide-induced DNA single- and double-strand breaks increased in UE1DP-1/tc- cells together with a rise in clonogenic sensitivity to etoposide, but an equal apoptotic sensitivity to etoposide. The increase in topoisomerase IIα promoter activity in UE1DP-1/tc- cells was shown to be due to S-phase initiation per se because it was blocked by ectopic expression of dominant neg. cyclin-dependent kinase 2. In conclusion, overexpression of E2F-1/DP-1 in U-2OS-TA cells is sufficient to increase clonogenic sensitivity to both topoisomerase I- and II-targeted anticancer drugs. However, the mechanism by which this occurs appears to be qual. different. The UE1DP-1 cell model may be used to elucidate post-DNA damage mechanisms of cell death induced by topoisomerase I-directed anticancer agents.
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s Sehested Maxwell/AU
L14 83 SEHESTED MAXWELL/AU

=> s l14 and topoisomerase
13765 TOPOISOMERASE
1840 TOPOISOMERASES
14064 TOPOISOMERASE
(TOPOISOMERASE OR TOPOISOMERASES)
L15 40 L14 AND TOPOISOMERASE

=> s l15 and dioxypiperazine
6 DIOXYPIPERAZINE

```
L16          2 L15 AND DIOXYPIPERAZINE

=> dis l16 1-2 bib abs

L16  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2005:1004605  CAPLUS
DN   143:279366
TI   Cancer treatment with topoisomerase II inhibitor, a bis-
     dioxypiperazine and radiation
IN   Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul;
     Thougaard, Annemette; Jensen, Peter Buhl
PA   Topotarget A/S, Den.
SO   PCT Int. Appl., 28 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2005084754        A2    20050915    WO 2005-IB670           20050302
     WO 2005084754        A3    20060526
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     AU 2005219034        A1    20050915    AU 2005-219034          20050302
     CA 2557857           A1    20050915    CA 2005-2557857         20050302
     EP 1720612           A2    20061115    EP 2005-708755          20050302
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
             HR, LV, MK, YU
     JP 2007527428        T     20070927    JP 2007-501380          20050302
     US 20070185124       A1    20070809    US 2007-591847          20070109
PRAI GB 2004-4675         A     20040302
     WO 2005-IB670        W     20050302
AB   The present invention relates to a method of treatment of a tumor cell
     which comprises administering to a subject in need of treatment an
     effective amount of a topoisomerase-II poison, e.g. etoposide, in
     combination with a bis-dioxypiperazine, e.g. dexrazoxane,
     wherein said subject is further treated with radiation.

L16  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   1997:556108  CAPLUS
DN   127:145175
OREF 127:27889a
TI   Topoisomerase II poison and bis-dioxypiperazine
     derivative combination therapy
IN   Jensen, Peter Buhl; Sehested, Maxwell
PA   Jensen, Peter Buhl, Den.; Sehested, Maxwell
SO   PCT Int. Appl., 52 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
```

```
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 9725044           A1    19970717    WO 1997-DK13           19970110
         W:  AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, HU, IL, IS, JP,
             KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
             MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, TJ, TM,
             TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
             MR, NE, SN, TD, TG
     CA 2242406            A1    19970717    CA 1997-2242406        19970110
     AU 9713677            A     19970801    AU 1997-13677          19970110
     EP 874630             A1    19981104    EP 1997-900205         19970110
     EP 874630             B1    20030820
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     AT 247468             T     20030915    AT 1997-900205         19970110
     PT 874630             T     20040130    PT 1997-900205         19970110
     ES 2205164            T3    20040501    ES 1997-900205         19970110
     US 6265385            B1    20010724    US 1999-101499         19990308
PRAI DK 1996-22            A     19960111
     US 1996-603105        A     19960220
     WO 1997-DK13          W     19970110
AB   The present invention relates to a method for selectively killing tumor or
     metastatic cells within a defined compartment of the organism of a large
     mammal, in particular a human, said method comprising administering to a
     mammal an effective tumor- or metastasis-killing amount of a
     topoisomerase II poison except doxorubicin, and protecting
     non-tumorous tissue of the mammal against the toxic action of the
     topoisomerase II poison by administration of a bis-
     dioxypiperazine compound  In particular, the invention relates to a
     pharmaceutical kit for selectively killing tumor or metastatic cells
     within the central nervous system of a large mammal, in particular a
     human, said kit comprising: a) a dosage unit of a bis-
     dioxypiperazine and a pharmaceutically acceptable carrier, and b)
     a dosage unit of topoisomerase II poisons except doxorubicin and
     a pharmaceutically acceptable carrier.


=> s Kristjansen Paul/AU
L17          1 KRISTJANSEN PAUL/AU

=> dis l17 bib abs

L17  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2005:1004605  CAPLUS
DN   143:279366
TI   Cancer treatment with topoisomerase II inhibitor, a bis-dioxypiperazine
     and radiation
IN   Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul;
     Thougaard, Annemette; Jensen, Peter Buhl
PA   Topotarget A/S, Den.
SO   PCT Int. Appl., 28 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2005084754        A2    20050915    WO 2005-IB670          20050302
```

```
     WO 2005084754        A3    20060526
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     AU 2005219034        A1    20050915    AU 2005-219034         20050302
     CA 2557857           A1    20050915    CA 2005-2557857        20050302
     EP 1720612           A2    20061115    EP 2005-708755         20050302
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
             HR, LV, MK, YU
     JP 2007527428        T     20070927    JP 2007-501380         20050302
     US 20070185124       A1    20070809    US 2007-591847         20070109
PRAI GB 2004-4675         A     20040302
     WO 2005-IB670        W     20050302
AB   The present invention relates to a method of treatment of a tumor cell
     which comprises administering to a subject in need of treatment an
     effective amount of a topoisomerase-II poison, e.g. etoposide, in
     combination with a bis-dioxypiperazine, e.g. dexrazoxane, wherein said
     subject is further treated with radiation.


=> s Thougaard Annemette/AU
L18          3 THOUGAARD ANNEMETTE/AU

=> dis l18 1-3 bib abs

L18  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2007:510771  CAPLUS
DN   147:268549
TI   The histone deacetylase inhibitor PXD101 synergizes with 5-fluorouracil to
     inhibit colon cancer cell growth in vitro and in vivo
AU   Tumber, Anthony; Collins, Laura S.; Petersen, Kamille Dumong;
     Thougaard, Annemette; Christiansen, Sanne J.; Dejligbjerg,
     Marielle; Jensen, Peter Buhl; Sehested, Maxwell; Ritchie, James W. A.
CS   TopoTarget UK LTD, Abingdon, OX14 4RY, UK
SO   Cancer Chemotherapy and Pharmacology (2007), 60(2), 275-283
     CODEN: CCPHDZ; ISSN: 0344-5704
PB   Springer
DT   Journal
LA   English
AB   Histone deacetylase inhibitors (HDACi) inhibit the growth of cancer cells,
     and combinations of HDACi with established chemotherapeutics can lead to
     synergistic effects.  We have investigated effects of PXD101 (HDACi in
     phase II clin. trials) in combination with 5-fluorouracil, on tumor cell
     proliferation and apoptosis both in vitro and in vivo.  HCT116 cells were
     studied using proliferation and clonogenic assays.  Synergistic inhibition
     of proliferation and clonogenicity was determined by incubation with PXD101 and
     5-fluorouracil, and anal. using CalcuSyn software.  The effect of
     combining PXD101 and 5-fluorouracil on apoptosis was examined in vitro using
     PARP-cleavage and TUNEL.  Finally, the effectiveness of combining PXD101
     and 5-fluorouracil in vivo was tested using both HT-29 and HCT116
     xenograft models.  Synergistic inhibition of proliferation and
     clonogenicity was obtained when HCT116 cells were incubated with PXD101
```

and 5-fluorouracil. 5-fluorouracil combined with PXD101 also increased DNA fragmentation and PARP cleavage in HCT116 cells. Incubation with PXD101 down regulated thymidylate synthase expression in HCT116 cells. In vivo studies, using mouse HT29 and HCT116 xenograft models, showed improved redns. in tumor volume compared to single compound, when PXD101 and 5-fluorouracil were combined. PXD101 and 5-fluorouracil synergistically combine in their antitumor effects against colon cancer cells in vitro and show enhanced activity when combined in vivo. Based on the results presented herein, a rationale for the use of PXD101 and 5-fluorouracil in combination in the clinic has been demonstrated.

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:842431 CAPLUS
DN 145:284390
TI Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
AU Qian, Xiaozhong; LaRochelle, William J.; Ara, Gulshan; Wu, Frank; Petersen, Kamille Dumong; Thougaard, Annemette; Sehested, Maxwell; Lichenstein, Henri S.; Jeffers, Michael
CS CuraGen Corporation, Branford, CT, 06405, USA
SO Molecular Cancer Therapeutics (2006), 5(8), 2086-2095
CODEN: MCTOCF; ISSN: 1535-7163
PB American Association for Cancer Research
DT Journal
LA English
AB Histone deacetylase inhibitors represent a promising new class of anticancer agents. In the current investigation, we examined the activity of PXD101, a potent histone deacetylase inhibitor, used alone or in combination with clin. relevant chemotherapeutics (docetaxel, paclitaxel, and carboplatin), in preclin. in vitro and in vivo models of ovarian cancer. In vitro activity was examined in ovarian cancer and multidrug-resistant cell lines grown in monolayer culture, and in primary clin. ovarian cancer specimens grown in three-dimensional organoid culture. PXD101 was found to inhibit in vitro cancer cell growth at sub- to low micromolar IC50 potency, exhibited synergistic activity when used in combination with relevant chemotherapeutics, and effectively inhibited the growth of multidrug-resistant cells. In vivo, PXD101 displayed single-agent antitumor activity on human A2780 ovarian cancer s.c. xenografts which was enhanced via combination therapy with carboplatin. In support of these findings, PXD101 was shown to increase the acetylation of α-tubulin induced by docetaxel and the phosphorylation of H2AX induced by carboplatin. Taken together, these results support the clin. evaluation of PXD101 used alone or in combination therapy for the treatment of ovarian cancer.

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1004605 CAPLUS
DN 143:279366
TI Cancer treatment with topoisomerase II inhibitor, a bis-dioxypiperazine and radiation
IN Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul; Thougaard, Annemette; Jensen, Peter Buhl
PA Topotarget A/S, Den.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084754	A2	20050915	WO 2005-IB670	20050302
	WO 2005084754	A3	20060526		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005219034	A1	20050915	AU 2005-219034	20050302
	CA 2557857	A1	20050915	CA 2005-2557857	20050302
	EP 1720612	A2	20061115	EP 2005-708755	20050302
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	JP 2007527428	T	20070927	JP 2007-501380	20050302
	US 20070185124	A1	20070809	US 2007-591847	20070109
PRAI	GB 2004-4675	A	20040302		
	WO 2005-IB670	W	20050302		

AB The present invention relates to a method of treatment of a tumor cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane, wherein said subject is further treated with radiation.

```
=> s Jensen Peter Buhl/AU
L19         43 JENSEN PETER BUHL/AU

=> s l19 and topoisomerase
         13765 TOPOISOMERASE
          1840 TOPOISOMERASES
         14064 TOPOISOMERASE
                  (TOPOISOMERASE OR TOPOISOMERASES)
L20         23 L19 AND TOPOISOMERASE

=> s l20 and dioxypiperazine
             6 DIOXYPIPERAZINE
L21          2 L20 AND DIOXYPIPERAZINE

=> dis l21 1-2 bib abs

L21  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2005:1004605  CAPLUS
DN   143:279366
TI   Cancer treatment with topoisomerase II inhibitor, a bis-
     dioxypiperazine and radiation
IN   Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul; Thougaard,
     Annemette; Jensen, Peter Buhl
PA   Topotarget A/S, Den.
SO   PCT Int. Appl., 28 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
```

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084754	A2	20050915	WO 2005-IB670	20050302
	WO 2005084754	A3	20060526		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005219034	A1	20050915	AU 2005-219034	20050302
	CA 2557857	A1	20050915	CA 2005-2557857	20050302
	EP 1720612	A2	20061115	EP 2005-708755	20050302
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	JP 2007527428	T	20070927	JP 2007-501380	20050302
	US 20070185124	A1	20070809	US 2007-591847	20070109
PRAI	GB 2004-4675	A	20040302		
	WO 2005-IB670	W	20050302		

AB The present invention relates to a method of treatment of a tumor cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane, wherein said subject is further treated with radiation.

L21 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:556108 CAPLUS
DN 127:145175
OREF 127:27889a
TI Topoisomerase II poison and bis-dioxypiperazine derivative combination therapy
IN Jensen, Peter Buhl; Sehested, Maxwell
PA Jensen, Peter Buhl, Den.; Sehested, Maxwell
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9725044	A1	19970717	WO 1997-DK13	19970110
	W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2242406	A1	19970717	CA 1997-2242406	19970110
	AU 9713677	A	19970801	AU 1997-13677	19970110
	EP 874630	A1	19981104	EP 1997-900205	19970110
	EP 874630	B1	20030820		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

```
             IE, FI
     AT 247468            T     20030915    AT 1997-900205         19970110
     PT 874630            T     20040130    PT 1997-900205         19970110
     ES 2205164           T3    20040501    ES 1997-900205         19970110
     US 6265385           B1    20010724    US 1999-101499         19990308
PRAI DK 1996-22           A     19960111
     US 1996-603105       A     19960220
     WO 1997-DK13         W     19970110
AB   The present invention relates to a method for selectively killing tumor or
     metastatic cells within a defined compartment of the organism of a large
     mammal, in particular a human, said method comprising administering to a
     mammal an effective tumor- or metastasis-killing amount of a
     topoisomerase II poison except doxorubicin, and protecting
     non-tumorous tissue of the mammal against the toxic action of the
     topoisomerase II poison by administration of a bis-
     dioxypiperazine compound  In particular, the invention relates to a
     pharmaceutical kit for selectively killing tumor or metastatic cells
     within the central nervous system of a large mammal, in particular a
     human, said kit comprising: a) a dosage unit of a bis-
     dioxypiperazine and a pharmaceutically acceptable carrier, and b)
     a dosage unit of topoisomerase II poisons except doxorubicin and
     a pharmaceutically acceptable carrier.


=> dis hist

     (FILE 'HOME' ENTERED AT 17:03:06 ON 15 AUG 2008)

     FILE 'MEDLINE, BIOSIS, APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX,
     DISSABS, EMA, IFIPAT, NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH,
     USPATFULL, USPATOLD, USPAT2, WPIFV, WPINDEX, WSCA, WTEXTILES, EMBASE'
     ENTERED AT 17:03:41 ON 15 AUG 2008
L1             0 S TOPOISOMERSE(A)II(A)POISON
L2          1540 S TOPOISOMERASE(A)II(A)POISON
L3            21 S L2 AND (DIOXYPIPERAZINE OR PIPERAZINEDIONE)
L4             1 S PIPERAZINEDIONE(W)RADIATION
L5          5385 S PIPERAZINEDIONE
L6           786 S L5 AND RADIATION
L7           455 S L6 AND (ANTI(A)TUMOR)
L8           433 S L7 AND TOXICITY
L9           394 S L8 AND BIS
L10         6550 S (BIS AND ETHANEDIYL)
L11           67 S L8 AND (BIS AND ETHANEDIYL)
L12           59 S L11 AND IONIZING

     FILE 'CAPLUS' ENTERED AT 17:12:08 ON 15 AUG 2008
L13            2 S HOFLAND KENNETH/AU
L14           83 S SEHESTED MAXWELL/AU
L15           40 S L14 AND TOPOISOMERASE
L16            2 S L15 AND DIOXYPIPERAZINE
L17            1 S KRISTJANSEN PAUL/AU
L18            3 S THOUGAARD ANNEMETTE/AU
L19           43 S JENSEN PETER BUHL/AU
L20           23 S L19 AND TOPOISOMERASE
L21            2 S L20 AND DIOXYPIPERAZINE

=>
```